{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T21:07:25Z","timestamp":1649192845993},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T00:00:00Z","timestamp":1581638400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T00:00:00Z","timestamp":1581638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s00066-020-01593-0","type":"journal-article","created":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T17:02:41Z","timestamp":1581699761000},"page":"414-415","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Positronenemissionstomographie(PET)-geleitete Behandlung des Hodgkin-Lymphoms im fr\u00fchen Stadium mit g\u00fcnstigen Risikofaktoren: Endresultate der internationalen randomisierten Phase-III-HD16-Studie der Deutschen Hodgkin-Studiengruppe"],"prefix":"10.1007","volume":"196","author":[{"given":"Carsten","family":"Nieder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,14]]},"reference":[{"key":"1593_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1053\/j.seminhematol.2016.05.003","volume":"53","author":"PJ Br\u00f6ckelmann","year":"2016","unstructured":"Br\u00f6ckelmann\u00a0PJ, Angelopoulou\u00a0MK, Vassilakopoulos\u00a0TP (2016) Prognosticfactors in Hodgkin lymphoma. Semin Hematol 53:155\u2013164","journal-title":"Semin. Hematol."},{"key":"1593_CR2","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3322\/caac.21438","volume":"68","author":"S Shanbhag","year":"2018","unstructured":"Shanbhag\u00a0S, Ambinder\u00a0RF (2018) Hodgkin lymphoma: a review and update on recent progress. CA Cancer J Clin 68:116\u2013132","journal-title":"CA Cancer J Clin"},{"key":"1593_CR3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1053\/j.seminhematol.2016.05.004","volume":"53","author":"A Engert","year":"2016","unstructured":"Engert\u00a0A, Raemaekers\u00a0J (2016) Treatment of\u00a0early-stage Hodgkin lymphoma. Semin Hematol 53:165\u2013170","journal-title":"Semin. Hematol."},{"key":"1593_CR4","first-page":"CD008814","volume":"13;9","author":"J Franklin","year":"2017","unstructured":"Franklin\u00a0J, Eichenauer\u00a0DA, Becker\u00a0I et\u00a0al (2017) Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis. Cochrane Database Syst Rev 13;9:CD8814","journal-title":"Cochrane Database Syst Rev"},{"key":"1593_CR5","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1182\/blood-2017-10-772665","volume":"131","author":"PJ Br\u00f6ckelmann","year":"2018","unstructured":"Br\u00f6ckelmann\u00a0PJ, Sasse\u00a0S, Engert\u00a0A (2018) Balancing risk and benefit in early-stage classical Hodgkin lymphoma. Blood 131:1666\u20131678","journal-title":"Blood"},{"key":"1593_CR6","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1182\/blood-2018-01-827246","volume":"132","author":"DJ Straus","year":"2018","unstructured":"Straus\u00a0DJ, Jung\u00a0SH, Pitcher B et\u00a0al (2018) CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood 132:1013\u20131021","journal-title":"Blood"},{"key":"1593_CR7","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1200\/JCO.19.00964","volume":"37","author":"M Fuchs","year":"2019","unstructured":"Fuchs\u00a0M, Goergen\u00a0H, Kobe C et\u00a0al (2019) Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group. J Clin Oncol 37:2835\u20132845","journal-title":"J. Clin. Oncol."},{"key":"1593_CR8","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1053\/j.seminoncol.2018.01.005","volume":"44","author":"HJA Adams","year":"2017","unstructured":"Adams\u00a0HJA, Kwee\u00a0TC (2017) An evidence-based review on the value of interim FDG-PET in assessing response to therapy in lymphoma. Semin Oncol 44:404\u2013419","journal-title":"Semin Oncol"},{"key":"1593_CR9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/PPO.0000000000000336","volume":"24","author":"M Hutchings","year":"2018","unstructured":"Hutchings\u00a0M (2018) Improvements in imaging of Hodgkin lymphoma: positron emission tomography. Cancer\u00a0J 24:215\u2013222","journal-title":"Cancer J"},{"key":"1593_CR10","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","volume":"372","author":"J Radford","year":"2015","unstructured":"Radford\u00a0J, Illidge\u00a0T, Counsell\u00a0N et\u00a0al (2015) Results of a\u00a0trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma. N\u00a0Engl J Med 372:1598\u20131607","journal-title":"N Engl J Med"},{"issue":"10","key":"1593_CR11","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","volume":"35","author":"MPE Andre","year":"2017","unstructured":"Andre\u00a0MPE, Girinsky\u00a0T, Federico\u00a0M et\u00a0al (2017) Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: Final results of the randomized EORTC\/LYSA\/FIL H10 trial. J Clin Oncol 35(10):1786\u20131794","journal-title":"J. Clin. Oncol."},{"key":"1593_CR12","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/bjh.15566","volume":"184","author":"PJ Br\u00f6ckelmann","year":"2019","unstructured":"Br\u00f6ckelmann\u00a0PJ, McMullen\u00a0S, Wilson\u00a0JB et\u00a0al (2019) Patient and physician preferences for first-line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom. Br J Haematol 184:202\u2013214","journal-title":"Br J Haematol"},{"key":"1593_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16232","author":"I Lagerl\u00f6f","year":"2019","unstructured":"Lagerl\u00f6f\u00a0I, Holte\u00a0H, Glimelius\u00a0I et\u00a0al (2019) No excess long-term mortality in stage I\u2013IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy. Br J Haematol. https:\/\/doi.org\/10.1111\/bjh.16232","journal-title":"Br J Haematol"},{"key":"1593_CR14","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/PPO.0000000000000332","volume":"24","author":"L Specht","year":"2018","unstructured":"Specht\u00a0L (2018) Radiotherapy for Hodgkin lymphoma: reducing toxicity while maintaining efficacy. Cancer\u00a0J 24:237\u2013243","journal-title":"Cancer J"},{"key":"1593_CR15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/0284186X.2018.1512153","volume":"58","author":"A Edvardsson","year":"2019","unstructured":"Edvardsson\u00a0A, K\u00fcgele\u00a0M, Alkner\u00a0S et\u00a0al (2019) Comparative treatment planning study for mediastinal Hodgkin\u2019s lymphoma: impact on normal tissue dose using deep inspiration breath hold proton and photon therapy. Acta Oncol 58:95\u2013104","journal-title":"Acta Oncol"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-020-01593-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00066-020-01593-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-020-01593-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,13]],"date-time":"2021-02-13T20:53:53Z","timestamp":1613249633000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00066-020-01593-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,14]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["1593"],"URL":"https:\/\/doi.org\/10.1007\/s00066-020-01593-0","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,14]]},"assertion":[{"value":"14 February 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.\u00a0Nieder gibt an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}